PROCRIT

(erythropoietin)

ApprovedSmall molecule

WWim Janssens

PROCRIT is one of 420 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

419

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Metabolic SyndromeActive, not recruiting

Liver TransplantActive, not recruiting

Diabetic NephropathyCompleted

DeliriumCompleted

Iron Deficiency AnemiaActive, not recruiting

EncephalopathyRecruiting

Coronary Artery BypassActive, not recruiting

Autoimmune EncephalitisActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

Metabolic SyndromePreclinical

Active, not recruiting

Liver TransplantApproved

Active, not recruiting

Diabetic NephropathyPreclinical

Completed

DeliriumApproved

Completed

Iron Deficiency AnemiaPreclinical

Active, not recruiting

EncephalopathyPhase 3

Recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

Autoimmune EncephalitisApproved

Active, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

169 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

PROCRIT

WWim Janssens

Approved

1 2

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

8 3

Uloric

Takeda

Preclinical

2 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Lorelco

Sanofi

Preclinical

1 8

Activase

Flomax

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Encephalopathy

NCT05395195

Q1 2029

Phase 1Not yet recruiting

Erythropoietin

NCT06590155

Q2 2035

Recruiting

Immune Thrombocytopenia

NCT05931718

Clinical

Trials by Indication[1]

Erythropoietin18 trials

NAION Treatment With Oral Prednisolone and Erythropoietin Injection

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2·NCT03715881·99 enrolled

Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya

Completed·—·Phase 1/2·NCT03162588·37 enrolled

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

Completed·NNorth Texas Veterans Healthcare System·Phase 2·NCT03102021·25 enrolled

Show 15 more trials

REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial

Terminated·QQueen's University·Phase 3·NCT00319150·6 enrolled

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

Unknown status·—··NCT04573686·50 enrolled

Proliferative Effects of Erythropoietin on Human Endometrium

Completed·FFatih Sultan Mehmet Training and Research Hospital··NCT03060603·14 enrolled

Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery

Completed·CCardiochirurgia E.H.·N/A·NCT01265680·600 enrolled

Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI

Withdrawn·UUniformed Services University of the Health Sciences·Phase 2·NCT02148367

Effects of Erythropoietin for Cognitive Side-effects of ECT

Completed·MMartin Balslev Jørgensen·Phase 2·NCT03339596·60 enrolled

Erythropoietin and Platelet Activation Markers

Completed·MMedical University of Vienna·Phase 4·NCT01392612·12 enrolled

Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers

Unknown status·RRennes University Hospital·N/A·NCT00687518·14 enrolled

Renal Effects of Erythropoietin in Humans

Completed·UUniversity of Copenhagen·Phase 1·NCT01584921·16 enrolled

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

Completed·JJohns Hopkins University·Phase 2·NCT00737893·56 enrolled

Erythropoietin Spinal Cord Compression Randomized Trial

Terminated·SSunnybrook Health Sciences Centre·Phase 2/3·NCT00220675·7 enrolled

Erythropoietin in Hemolytic Uremic Syndrome

Completed·HHospital General de Niños Pedro de Elizalde·Phase 4·NCT03776851·24 enrolled

Anti-Restenosis After AMI by Erythropoietin

Unknown status·KKyoto Prefectural University of Medicine·Phase 4·NCT00423020·72 enrolled

Erythropoietin in HIE Neonate

Not yet recruiting·—·Phase 1·NCT06590155·3 enrolled

Erythropoietin to Improve Critical Care Patient Outcomes

Unknown status·UUniversity Hospital, Angers·Phase 3·NCT05080049·42 enrolled

Anemia6 trials

Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients

Completed·MMahidol University··NCT01049711·152 enrolled

A Safety Study of Pentoxifylline for the Treatment of Anemia

Terminated·FFresenius Medical Care North America·Phase 2·NCT01102218·48 enrolled

Roxadustat for Anemia in Patients With CKD

Unknown status·SShenzhen Second People's Hospital··NCT04502537·200 enrolled

Show 3 more trials

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Unknown status·PPeking University·Phase 4·NCT03010579·70 enrolled

Practical Anemia Bundle for SusTained Blood Recovery

Completed·MMayo Clinic·Phase 2·NCT05167734·100 enrolled

Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

Unknown status·RRabin Medical Center·Phase 4·NCT00418119·10 enrolled

Brain Injury3 trials

Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT01913340·50 enrolled

Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury

Completed·—··NCT03061565·356 enrolled

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

Terminated·—·Phase 2·NCT00589953·22 enrolled

Encephalopathy3 trials

High-dose Erythropoietin for Asphyxia and Encephalopathy

Completed·UUniversity of California, San Francisco·Phase 3·NCT02811263·500 enrolled

Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)

Recruiting·IImperial College London·Phase 3·NCT05395195·504 enrolled

Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy

Unknown status·—·Phase 3·NCT03163589·40 enrolled

Cerebral Palsy3 trials

Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1

Completed·MMinYoung Kim, M.D.·Phase 1·NCT01586052·11 enrolled

Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy

Completed·SSung Kwang Medical Foundation·N/A·NCT01193660·105 enrolled

Erythropoietin Therapy for Children With Cerebral Palsy

Completed·—·Phase 2·NCT01650415·11 enrolled

46 more indications

Acute Kidney Injury2 trials

The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

Terminated·NNanjing First Hospital, Nanjing Medical University·N/A·NCT03007537·101 enrolled

Erythropoietin Role in Acute Kidney Injury

Terminated·SSaint-Joseph University·N/A·NCT03401710·134 enrolled

Asphyxia2 trials

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

Completed·SSheri Kashmir Institute of Medical Sciences·Phase 2/3·NCT02002039·100 enrolled

Neonatal Erythropoietin in Asphyxiated Term Newborns

Completed·UUniversity of California, San Francisco·Phase 1·NCT00719407·24 enrolled

Neuropathy2 trials

Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Completed·—·Phase 1/2·NCT04469777·20 enrolled

Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)

Unknown status·TTehran University of Medical Sciences·Phase 3·NCT02376881·24 enrolled

Altitude2 trials

Pharmacological Countermeasures for High Altitude

Active, not recruiting·—·Phase 4·NCT05300477·18 enrolled

Colorado-Oregon Altitude Study

Completed·UUniversity of Oregon·Phase 4·NCT05734716·121 enrolled

Myelodysplastic Syndromes2 trials

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Terminated·LLarry Cripe, MD·Phase 2·NCT00379912·15 enrolled

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003138·118 enrolled

Autoimmune Encephalitis1 trial

Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

Withdrawn·SSeoul National University Hospital·Phase 4·NCT03004209

Acute Mountain Sickness1 trial

Erythropoietin in the Prevention of Acute Mountain Sickness

Completed·UUniversity of Ulsan·Phase 4·NCT01665781·39 enrolled

Bipolar Disorder1 trial

Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder

Completed·LLars Vedel Kessing, professor, MD, DMSc.·Phase 2·NCT00916552·83 enrolled

Mood Disorder1 trial

Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders

Completed·LLars Vedel Kessing·Phase 2·NCT03315897·103 enrolled

Cerebral Perfusion1 trial

Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

Completed·—·Phase 2·NCT02603406·44 enrolled

Chronic Hepatitis1 trial

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01023035·687 enrolled

Premature Infants1 trial

Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT03110341·400 enrolled

Kidney Transplant1 trial

The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

Unknown status·—·Phase 1·NCT00617474·50 enrolled

Myocardial Infarction1 trial

Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)

Completed·DDeutsches Herzzentrum Muenchen·Phase 3·NCT00390832·138 enrolled

Pediatric1 trial

Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

Unknown status·SSeoul National University Hospital·N/A·NCT03882060·60 enrolled

Hemorrhage1 trial

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Completed·ZZhengzhou University·Phase 2·NCT03914690·316 enrolled

Stress Response1 trial

Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients

Unknown status·TTehran University of Medical Sciences·Phase 2·NCT00622934·20 enrolled

Treatment Outcome1 trial

Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome

Unknown status·MMedical University of Vienna·Phase 3·NCT00348738·300 enrolled

CABG1 trial

PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

Recruiting·FFederal University of São Paulo·Phase 2·NCT06542393·120 enrolled

Methylprednisolone1 trial

Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)

Terminated·NNiguarda Hospital·Phase 3·NCT00561067·10 enrolled

Myelodysplastic Syndrome1 trial

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00520468·15 enrolled

Completed·JJinling Hospital, China·N/A·NCT01823029·387 enrolled

Metabolic Syndrome1 trial

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

Not yet recruiting·FFayoum University··NCT06983756·66 enrolled

Acute Myocardial Infarction1 trial

Erythropoietin in Acute Myocardial Infarction

Unknown status·—·Phase 2·NCT00149058·124 enrolled

Delirium1 trial

EPO for Postop Delirium in Elderly Patients

Completed·YYonsei University·Phase 4·NCT06178835·76 enrolled

Optic Neuritis1 trial

Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis

Completed·IInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbH·Phase 2·NCT00355095·40 enrolled

Stroke1 trial

Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

Unknown status·—·Phase 1/2·NCT04013646·24 enrolled

Cognitive Function1 trial

Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans

Unknown status·UUniversity of Zurich·Phase 1/2·NCT01889056·32 enrolled

Orthopedic Surgery1 trial

Blood Management in Orthopedic Surgery

Completed·SSanquin Research & Blood Bank Divisions·Phase 4·NCT00998088·2,598 enrolled

Hip Fracture1 trial

Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT01154491·303 enrolled

Insulin resistance1 trial

Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

Completed·—·N/A·NCT00793767·10 enrolled

Multiple Sclerosis1 trial

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis

Unknown status·RRigshospitalet, Denmark·Phase 2·NCT01144117·56 enrolled

Oral Lichen Planus1 trial

Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus

Unknown status·—·Phase 3·NCT06135259·18 enrolled

Chronic Kidney Disease1 trial

A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Completed·HHospital Authority, Hong Kong·N/A·NCT00563355·66 enrolled

Low Birth Weight1 trial

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

Completed·NNICHD Neonatal Research Network·Phase 2/3·NCT01203514·318 enrolled

Type 2 Diabetes1 trial

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT00535925·850 enrolled

Malaria1 trial

Randomized Trial of Erythropoietin During Cerebral Malaria

Unknown status·—·Phase 2/3·NCT00697164·120 enrolled

Children1 trial

Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

Unknown status·BBlau Farmaceutica S.A.·Phase 3·NCT05704894·320 enrolled

Liver Disease1 trial

Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease

Completed·NNorthwestern University·Phase 1·NCT03842254·6 enrolled

Anaemia1 trial

Effect of Probiotic Supplementation on Resistant Anaemia to Erythropoietin in Chronic Kidney Disease Patients.

Completed·BBadr University·Phase 3·NCT07296146·80 enrolled

Liver Transplant Rejection1 trial

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

Completed·NNorthwestern University·Approved·NCT05325073·9 enrolled

Diabetic Nephropathy1 trial

Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy

Completed·HHanzla Arshad·Preclinical·NCT07786168·64 enrolled

Unspecified1 trial

Exosome Proteomics to Detect EPO

Unknown status·MMorten Hostrup, PhD·N/A·NCT03700515·72 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 1, 1989

EPOGEN/PROCRIT

NDA BLA103234

Jun 1, 1989

PROCRIT

BLA BLA103234

Dec 31, 1990

EPOGEN/PROCRIT

NDA BLA103234

Apr 1, 1993

EPOGEN/PROCRIT

NDA BLA103234

Jun 29, 1994

EPOGEN/PROCRIT

NDA BLA103234

Dec 23, 1996

EPOGEN/PROCRIT

NDA BLA103234

Jul 26, 1999

EPOGEN/PROCRIT

NDA BLA103234

Sep 29, 2000

EPOGEN/PROCRIT

NDA BLA103234

May 7, 2003

EPOGEN/PROCRIT

NDA BLA103234

May 21, 2004

EPOGEN/PROCRIT

NDA BLA103234

Jun 30, 2004

EPOGEN/PROCRIT

NDA BLA103234

Oct 19, 2004

EPOGEN/PROCRIT

NDA BLA103234

Nov 10, 2004

EPOGEN/PROCRIT

NDA BLA103234

Oct 26, 2005

EPOGEN/PROCRIT

NDA BLA103234

Oct 27, 2005

EPOGEN/PROCRIT

NDA BLA103234

May 11, 2006

EPOGEN/PROCRIT

NDA BLA103234

Mar 9, 2007

EPOGEN/PROCRIT

NDA BLA103234

Nov 8, 2007

EPOGEN/PROCRIT

NDA BLA103234

Dec 17, 2007

EPOGEN/PROCRIT

NDA BLA103234

Mar 7, 2008

EPOGEN/PROCRIT

NDA BLA103234

Nov 19, 2008

EPOGEN/PROCRIT

NDA BLA103234

Nov 19, 2008

EPOGEN/PROCRIT

NDA BLA103234

Oct 13, 2009

EPOGEN/PROCRIT

NDA BLA103234

Jan 11, 2010

EPOGEN/PROCRIT

NDA BLA103234

Feb 16, 2010

EPOGEN/PROCRIT

NDA BLA103234

Jun 24, 2011

EPOGEN/PROCRIT

NDA BLA103234

Jun 24, 2011

EPOGEN/PROCRIT

NDA BLA103234

Jun 24, 2011

EPOGEN/PROCRIT

NDA BLA103234

May 31, 2012

EPOGEN/PROCRIT

NDA BLA103234

Mar 27, 2013

EPOGEN/PROCRIT

NDA BLA103234

Dec 31, 2013

EPOGEN/PROCRIT

NDA BLA103234

Apr 13, 2017

EPOGEN/PROCRIT

NDA BLA103234

Apr 13, 2017

EPOGEN/PROCRIT

NDA BLA103234

Sep 29, 2017

EPOGEN/PROCRIT

NDA BLA103234

Sep 29, 2017

EPOGEN/PROCRIT

NDA BLA103234

Jul 25, 2018

EPOGEN/PROCRIT

NDA BLA103234

Apr 30, 2024

EPOGEN/PROCRIT

NDA BLA103234

Sources

References

[1]
ClinicalTrials.gov — 84 trial records for erythropoietin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — erythropoietin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for erythropoietin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA BLA103234). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

PROCRIT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2029

Q2 2035

Trials by Indication[1]

Erythropoietin18 trials

Anemia6 trials

Brain Injury3 trials

Encephalopathy3 trials

Cerebral Palsy3 trials

Acute Kidney Injury2 trials

Asphyxia2 trials

Neuropathy2 trials

Altitude2 trials

Myelodysplastic Syndromes2 trials

Autoimmune Encephalitis1 trial

Acute Mountain Sickness1 trial

Bipolar Disorder1 trial

Mood Disorder1 trial

Cerebral Perfusion1 trial

Chronic Hepatitis1 trial

Premature Infants1 trial

Kidney Transplant1 trial

Myocardial Infarction1 trial

Pediatric1 trial

Hemorrhage1 trial

Stress Response1 trial

Treatment Outcome1 trial

CABG1 trial

Methylprednisolone1 trial

Myelodysplastic Syndrome1 trial

Aortic Valve Replacement1 trial

Coronary Artery Bypass1 trial

Immune Thrombocytopenia1 trial

Iron deficiency anemia1 trial

Metabolic Syndrome1 trial

Acute Myocardial Infarction1 trial

Delirium1 trial

Optic Neuritis1 trial

Stroke1 trial

Cognitive Function1 trial

Orthopedic Surgery1 trial

Hip Fracture1 trial

Insulin resistance1 trial

Multiple Sclerosis1 trial

Oral Lichen Planus1 trial

Chronic Kidney Disease1 trial

Low Birth Weight1 trial

Type 2 Diabetes1 trial

Malaria1 trial

Children1 trial

Liver Disease1 trial

Anaemia1 trial

Liver Transplant Rejection1 trial

Diabetic Nephropathy1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News